To evaluate whether the use of angiotensin-converting enzyme (ACE) inhibitors and statins is associated with a lower risk of incident mobility limitation in older community dwelling adults.DESIGN:
Longitudinal cohort study.SETTING:
Health, Aging and Body Composition (Health ABC) study.PARTICIPANTS:
Three thousand fifty-five participants who were well functioning at baseline (no mobility limitations).MEASUREMENTS:
Summated standardized daily doses (low, medium, high) and duration of ACE inhibitor and statin use were computed. Mobility limitation (two consecutive self-reports of having any difficulty walking one-quarter of a mile or climbing 10 steps without resting) was assessed every 6 months after baseline. Multivariable Cox proportional hazards analyses were conducted, adjusting for demographics, health status, and health behaviors.RESULTS:
At baseline, 15.2% used ACE inhibitors and 12.9% used statins; use of both was greater than 25% by Year 6. Over 6.5 years of follow-up, 49.8% had developed mobility limitation. In separate multivariable models, neither ACE inhibitor (multivariate hazard ratio (HR) = 0.95, 95% confidence interval (CI) = 0.82–1.09) nor statin use (multivariate HR = 1.02, 95% CI = 0.87–1.17) was associated with lower risk of mobility limitation. Similar findings were seen in analyses examining dose–response and duration–response relationships and a sensitivity analysis restricted to those with hypertension.CONCLUSION:
ACE inhibitors and statins widely prescribed to treat hypertension and hypercholesterolemia, respectively, do not lower risk of mobility limitation, an important indicator of quality of life.